Viral Vector Purification via Transgene Protein Capture

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing methods for purifying viral vectors for gene therapy are inadequate in removing transgene protein contaminants, which can lead to side effects and immune responses when systemically administered.

Innovation Solution

A method involving multiple chromatography steps, including a transgene protein capture step using a first chromatography matrix capable of selectively binding the transgene protein contaminant, and subsequent steps to recover the viral vector, thereby separating it from the contaminant.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional purification processes are used, then viral vectors are produced efficiently, but transgene protein contaminants co-purify with the viral vector

Engineering Contradiction:

Improveviral vector production efficiencyVSAvoidpurification purity

Core Design Contradiction:

ProductivityVSManufacturing precision

Solution Approach 1:

The purification process is divided into multiple sequential chromatography steps, each targeting specific contaminants. The first chromatography step removes transgene protein contaminants while the second step further purifies the viral vector, achieving both high productivity and high purity through segmented processing

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The harmful transgene protein contaminants are selectively extracted and removed from the viral vector preparation through specific chromatography steps. The first chromatography step specifically targets and removes transgene protein contaminants, separating them from the desired viral vector product

Inventive Principle:

Principle #2Taking out (Extraction)

2Device complexity

If transgene protein contaminants are not sufficiently reduced, then production process is simpler, but side effects and immune responses occur when systemically administered

Engineering Contradiction:

Improvepurification process complexityVSAvoidside effects and immune responses

Core Design Contradiction:

Device complexityVSObject-affected harmful factors

Solution Approach 1:

The first chromatography step is performed as a preliminary action to remove transgene protein contaminants before final viral vector formulation. This preliminary purification step prevents harmful factors from entering the final product, ensuring patient safety while maintaining a manageable process complexity

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

Chromatography matrices serve as intermediary substances that selectively bind and remove transgene protein contaminants. These intermediary materials facilitate the separation of harmful contaminants from the desired viral vector without requiring complex processing equipment

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method effectively reduces and eliminates transgene protein contaminants, resulting in a viral vector product that is substantially free of contaminants, improving the safety and efficacy of gene therapy treatments.

Implementation Method 1

contacting a composition comprising the viral vector and a transgene protein contaminant with a first chromatography matrix capable of selectively binding the transgene protein contaminant

Methodology Applied

Scientific EffectAdsorption: Adsorption